NDA Reviews Will Be Risk-Based Under FDA’s GMP Initiative
This article was originally published in The Pink Sheet Daily
Executive Summary
The Center for Drug Evaluation & Research will apply a risk-based approach to manufacturing aspects of NDA review, Office of Compliance Director David Horowitz said